...in order for TB innovations to be scaled, we need to put the countries and people affected by TB front and center.
NEW YORK (PRWEB) September 27, 2018
This past weekend at the TB Innovation Summit in New York City, Everwell Health Solutions and SureAdhere Mobile Technology, Inc. announced they will formally merge companies and integrate their technologies to create a unified platform for medication monitoring in the battle against tuberculosis (TB) and other diseases. These two social enterprise corporations, both of which focus heavily on medication adherence support for TB, will be able to improve care and offer more choices to patients and providers by working together.
Andrew Cross, CEO of Everwell said, “I’m thrilled about this partnership– Everwell shares our core values with SureAdhere - open collaboration, empowering patients, and supporting personalized, patient-centric care. Bringing together our combined experiences, we can build solutions that are global in scale and appropriate for patients in individual contexts.”
Both Everwell (with their Everwell Hub that uniquely integrates 99DOTS with other digital adherence solutions) and SureAdhere (with their Video Observed Therapy [VOT] platform) have a strong history of working with key organizations in the public health space. Everwell has received significant support from the Bill & Melinda Gates Foundation, USAID and DFID; SureAdhere works closely with the StopTB Partnership’s Accelerator for Impact (a4i). To date, Everwell’s efforts have focused on South Asia and Eastern Africa, including a deep partnership with the Government of India’s public and private sector TB program; SureAdhere has primarily been working in North America, Europe and Asia. Both companies were formed by researchers dedicated to making evidenced-based solutions accessible everywhere they are needed to support global TB elimination efforts. Everwell’s and SureAdhere’s solutions have been used to monitor treatment for over 185,000 TB patients in seven countries around the world.
Kelly Collins, CEO of SureAdhere said, “By joining forces with Everwell, we can significantly improve the impact we’re having on TB treatment adherence. This combined effort will allow us to focus on what really matters—giving TB patients and practitioners options in the fight against the world’s deadliest infectious disease.”
SureAdhere will operate as a subsidiary of Everwell, and will maintain its current company leadership as the companies work together to integrate their technologies. With continued support from the Bill and Melinda Gates Foundation, USAID, a4i and others, the companies will partner with National TB Programs and NGOs across eight countries in Asia, Africa and Eastern Europe in 2018 to implement scalable, patient-centered monitoring options without forcing programs to adopt multiple disconnected technologies.
Lucica Ditiu, Executive Director of the Stop TB Partnership said, “I commend Everwell and SureAdhere for being forward-thinking in terms of how innovators should collaborate and work together. We are excited to be working with both companies to show that in order for TB innovations to be scaled, we need to put the countries and people affected by TB front and center.”
Everwell Health Solutions is a healthcare technology startup company based in Bangalore, India co-founded by Andrew Cross and Bill Thies. Everwell’s mission is to use digital technology to empower patients to self-administer their drug treatments while enabling healthcare professionals to identify in real-time which patients require additional outreach to support high adherence. The Everwell Hub is an integrated adherence and patient management platform that allows adherence aggregation from many digital monitors such as 99DOTS, Wisepill’s evriMED device, and going forward: VOT. For more information, visit http://everwell.org/ and/or https://www.99dots.org.
SureAdhere is a San Diego-based provider of a secure and affordable, mobile health platform that enables remote medication adherence monitoring through video technology for patients with TB and other diseases. Co-Founded by Dr. Richard Garfein and led by CEO Kelly Collins, SureAdhere’s primary focus is on assuring adherence globally to complex treatment regimens for TB. Originating from National Institutes of Health-funded research, SureAdhere’s platform is evidence-based and informed by years of stakeholder input. For more information, visit http://www.sureadhere.com.
About the TB Innovation Summit
In the lead-up to the UN High-Level Meeting on TB, the Stop TB Partnership, Johnson & Johnson, United Nations Foundation, Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the World Economic Forum co-hosted the TB Innovation Summit on Sunday, 23 September 2018 in New York City. The Summit brought together a unique blend of private- and public-sector leaders, as well as TB survivors, country decision-makers, academics, civil society and community leaders, donors, and technical agencies. For more information, visit http://www.stoptb.org/siif/events/tbis.asp.